Study of Panobinostat in Patients With Neuroendocrine Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Neuroendocrine Tumors
Interventions
DRUG

panobinostat (LBH589)

Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.

Trial Locations (1)

53792

University of Wisconsin, Madison, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Wisconsin, Madison

OTHER